Britain's competition authority has fined drugmaker GlaxoSmithKline plc 37.6 million pounds ($54.5 million) for stalling the potential entry of generic competitors of an anti-depressant drug Seroxat into the marketplace.
News | Business, Atlanta Journal-Constitution: Business
Fri, 02/12/2016 - 3:47am
Britain's competition authority has fined drugmaker GlaxoSmithKline plc 37.6 million pounds ($54.5 million) for stalling the potential entry of generic competitors of an anti-depressant drug Seroxat into the marketplace.